GSK: promising results in hepatitis drug trial
(CercleFinance.com) - On Friday GSK released the results of a phase 2a trial suggesting that its experimental hepatitis drug had the potential to eliminate the disease after four weeks of treatment.
According to the laboratory, GSK'836 - which belongs to the category of antisense oligonucleotides - resulted in significant reductions in HBsAg (virus surface antigen) and the disease DNA in the 31 patients who participated in the study.
In its chronic form, hepatitis B affects nearly 260 million people worldwide and causes close to 900,000 deaths each year, due to liver failure or liver cancer.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
According to the laboratory, GSK'836 - which belongs to the category of antisense oligonucleotides - resulted in significant reductions in HBsAg (virus surface antigen) and the disease DNA in the 31 patients who participated in the study.
In its chronic form, hepatitis B affects nearly 260 million people worldwide and causes close to 900,000 deaths each year, due to liver failure or liver cancer.
Copyright (c) 2020 CercleFinance.com. All rights reserved.